Denali Therapeutics Inc.
DNLI
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also developsā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$19.46
Price-1.07%
-$0.21
1Y
Price
Market Cap
$3.088b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-33.3%
3y CAGR+26.2%
5y CAGREarnings
-$508.017m
+0.9%
1y CAGR-70.5%
3y CAGR-39.0%
5y CAGREPS
-$2.88
+3.0%
1y CAGR-51.7%
3y CAGR-23.9%
5y CAGRBook Value
$926.098m
$1.266b
Assets$339.925m
Liabilities$40.047m
DebtDebt to Assets
3.2%
-0.1x
Debt to EBITDAFree Cash Flow
-$419.226m
+0.7%
1y CAGR-4.5%
3y CAGR-13.7%
5y CAGRNo items found.
Press Releases
Statements and updates from the company